Canaccord analyst Gary Nachman lowered the firm's price target on Adma Biologics to $18 from $21 and keeps a Buy rating on the shares. The firm said 1Q26 was a reset quarter for the company with results that fell short and guidance lowered mainly due to pressure on Bivigam within the standard IG market. Importantly, key product and value driver Asceniv held up pretty well in 1Q.
